Psoriasis is a systemic immune-inflammatory disease characterized by chronic or recurrent skin symptoms, psoriatic arthritis, enthesopathy, and uveitis. Psoriasis has recently been published to appear with various autoimmune disorders, but the coexistence has been systematically reviewed by only a few studies until now. In the present study, charts and electronic database of 4344 patients with various systemic autoimmune disorders, under regular medical control at our department, were reviewed retrospectively searching for association with psoriasis. Hereby, we demonstrate 25 psoriatic patients coinciding with various systemic autoimmune diseases. The coexistence of psoriasis and autoimmune diseases resulted in the worsening of the clinical outcome of the autoimmune diseases as indicated by higher frequency and dosages of glucocorticoid use, need for biologicals, and other comorbidities. These results suggest common environmental and genetic background as well as therapeutic possibilities in the future.

1. Introduction

Autoimmunity is characterized by the breakdown of self-tolerance leading to a state of abnormal humoral and cell-mediated responses against self-components. Psoriasis is an immune-inflammatory skin disease affecting 2-3% of the general population which can be associated with psoriatic arthritis (PsA), enthesopathy, uveitis, and an increased prevalence of cardiovascular morbidity [1]. The association between psoriasis and systemic autoimmunity, rheumatic diseases is rare and little is known about its exact incidence. The pathogenesis of both disease entities involves genetic background and environmental triggers. A potential role of molecular mimicry has previously been described in the pathogenesis not only of autoimmune disease but also of psoriasis [2]. Several autoantigens have been implicated in psoriasis, amongst which are keratin 13 (K13), heterogeneous nuclear ribonucleoprotein-A1 (hnRNP-A1), and Rab coupling protein isoform 3 (FLJ00294) (RAB11FIP1), although the epidermal autoantigens have not been conclusively identified [3].

Underlying the importance of genetic associations, previously a clear correlation has been shown between psoriasis and risk of the development of diseases with autoimmune background, such as rheumatoid arthritis (RA), type 1 diabetes, celiac disease, or Crohn’s disease, based on the single nucleotide polymorphism (SNP) analysis of the TNFAIP3 gene [4].

In this work, we demonstrate 25 patients with psoriasis and various systemic autoimmune diseases. Among the patients with autoimmune diseases included in our database we selected those who were associated with psoriasis. Our survey aimed to determine the prevalence of coinciding psoriasis in autoimmune conditions and whether psoriasis has an impact on the outcome of associated autoimmune diseases.
Institute of Rheumatology and Physiotherapy, were systematically reviewed searching for psoriasis as comorbidity. As psoriasis associated with the highest frequency to RA and SLE, the same number of patients with and without psoriasis was selected and matched according to gender and age at onset, and as such case-control study could be performed. Patients in these subgroups were compared regarding the onset of the autoimmune diseases, clinical symptoms, and disease duration, as well as dose of corticosteroid and response to conventional and biological immunosuppressive therapies. In case of other autoimmune diseases only few patients belonged to subgroups with psoriasis; therefore a case-control study would not have been informative by statistical respect. Patients with psoriatic arthritis fulfilled the diagnostic criteria by laboratory markers, symptoms, and radiographic images and were distinguished from the joint manifestations of the above-mentioned autoimmune diseases [1, 5–16]. Psoriasis coexisted with SLE (n = 8), rheumatoid arthritis (n = 5), primary Sjögren’s syndrome (n = 5), primary Raynaud’s syndrome (n = 4), primary systemic vasculitis (n = 3), APS (n = 2), systemic sclerosis (n = 2), UCTD (n = 1), polymyositis (n = 1), and MCTD (n = 1). Various other comorbidities also associate with different autoimmune diseases, such as hypertension, cryral arthritis, interstitial lung disease, ischemic heart disease, cataract, and glaucoma.

2.1. Study Population. Out of the 4344 investigated patients (1450 with RA, 835 with Sjögren’s syndrome, 807 with SLE, 486 with Raynaud’s syndrome, 113 with undifferentiated connective diseases (UCTD), 313 with primary antiphospholipid syndrome (PAPS), 144 with polymyositis (PM), 127 with primary systemic vasculitis, 85 with systemic sclerosis, and 69 with mixed connective tissue diseases (MCTD)), 25 had coinciding psoriasis. Psoriatic arthritis was present in 14 cases. All patients fulfilled the corresponding classification criteria of the above-mentioned autoimmune diseases [1, 5–16]. Psoriasis coexisted with SLE (n = 8), rheumatoid arthritis (n = 5), primary Sjögren’s syndrome (n = 5), primary Raynaud’s syndrome (n = 4), primary systemic vasculitis (n = 3), APS (n = 2), systemic sclerosis (n = 2), UCTD (n = 1), polymyositis (n = 1), and MCTD (n = 1). Various other comorbidities also associate with different autoimmune diseases, such as hypertension, crystal arthritis, interstitial lung disease, ischemic heart disease, cataract, and glaucoma.

2.2. Data Collection. The clinical and laboratory data were collected from the institute’s electronic patient databases from inpatient and outpatient visits. The following diseases were investigated: SLE, primary systemic vasculitis, PAPS, UCTD, primary Raynaud’s syndrome, PM, systemic sclerosis, MCTD, primary Sjögren’s disease, and RA. Each specific disease was treated as an outcome variable. All diagnoses for these conditions were recorded from September 2007 to November 2013. In our database the following data were detected: age at the onset of the autoimmune diseases, clinical symptoms, immune serology, associated diseases, disease duration, coexistence of psoriatic arthritis, actual clinical state, and average dose of corticosteroid, immune suppressive therapy, and response to the therapy.

2.3. Statistical Analysis. All statistical analyses were performed using IBM SPSS 20 software. Fisher’s exact test was utilized to assess the average age of appearance of psoriasis and psoriatic arthritis and Mann-Whitney U test was performed to measure the average of corticosteroid usage.

3. Results

We determined the frequency of psoriasis in various autoimmune diseases and also assessed the rate of the psoriatic arthritis. We also aimed to compare demographic and disease-specific characteristics of RA and SLE with and without associating psoriasis.

There were 25 eligible individuals who fulfilled the criteria for psoriasis in the study population. The frequency of coinciding psoriasis was 0.99% in RA, 0.34% in SLE, 0.59% in Sjögren’s syndrome, 0.82% in Raynaud’s syndrome, 3.29% in systemic vasculitis, 6.3% in PAPS, 0.69% in PM, 2.35% in systemic sclerosis, 1.17% in UCTD, and 1.44% in MCTD. Out of the psoriatic cases 62.5% (n = 15) had psoriatic arthritis. Compared to the estimated vary of the population from 0.3% to 1% [15]. Psoriatic arthritis was diagnosed and distinguished from the musculoskeletal manifestations of the autoimmune diseases by the CASPAR criteria [16]. The median (min-max) age at autoimmune disease onset was 48 (24–68) years. Of those with psoriasis 12% were male and 88% were female. In 18 patients psoriasis developed first. In psoriatic patients who also suffered from different kinds of autoimmune diseases an increased rate of comorbidities was observed.

The second goal was to analyze demographic characteristics and the outcome of clinical symptoms in RA and SLE. In the case-control study the same number of patients with and without psoriasis was selected and matched out of our entire RA and SLE population. Demographic and disease-specific and treatment-associated data were compared in psoriatic and nonpsoriatic SLE and RA groups. The average age of appearance of psoriasis was 48 (24–68) years. The female to male ratio was 3:22 (12% and 88%). The appearance of psoriasis before and after the age of 40 years was similar (13/11 or 54% and 46%); however the frequency of psoriatic arthritis was significantly higher after 40 years of age (1/14 or 7% and 93%). Significantly higher doses of glucocorticoid (GC) were required in the SLE with psoriasis group (16.88 (10–30)) compared to SLE without psoriasis (11.4 (7.5–20)) (Tables 3 and 4). On the contrary in RA patients with psoriasis both the number of patients on GC and both the used GC doses were lower as compared to those with RA patients without associating psoriasis (Tables 1 and 2). The fact can be explained by differences in the usage of biological therapies, as all patients from the RA + psoriasis group were on TNF-alpha inhibitors, while in the control group only 1 patient received biological therapy. Both the SLE- and RA-associated psoriasis groups required intensified immune suppressive therapy. The association of psoriasis in both RA and SLE groups was characterized by worse laboratory markers, diseases outcome, and response to therapy. In the RA + psoriasis group 4 patients (80%) had other coinciding diseases, such as hypertension, neurofibromatosis, Sjögren’s syndrome, and systemic sclerosis, as compared to the RA group where 2 patients (40%) had hypertension and Sjögren’s syndrome. There were no significant differences of the immunological serology markers between the 2 groups. The responses to disease-modifying antirheumatic drugs (DMARDs) therapy were significantly worse in the RA + psoriasis group, since none of the patients responded or had side effects of the
| The age of RA onset | Comorbidity | Immunoserology | Actual clinical status | DMARD therapy | Response to DMARD | Corticosteroids (mg PED) | Biological therapy | Response to biology therapy | Psoriatic arthritis |
|-------------------|-------------|----------------|------------------------|---------------|------------------|-------------------------|-------------------|-----------------------------|-------------------|
| 63 yrs            | Hypertension | ANA, ACPA     | Remission              | Sulfasalazine-leukopenia, oral methotrexate-gastrointestinal side effect, cyclosporine-with golimumab | Nonresponder     | —                        | Golimumab         | Remission                   | Axial             |
| 46 yrs            | —            | RF, ACPA, ANA | Remission              | Oral methotrexate-ineffective, sulfasalazine-gastrointestinal side effect | Nonresponder     | —                        | Etanercept         | Remission                   | Peripheral        |
| 59 yrs            | Systemic sclerosis | RF, ACPA, ANA | Remission              | Chloroquine-gastrointestinal side effect, sulfasalazine | Nonresponder     | —                        | Adalimumab-ineffective, rituximab | Remission                   | Peripheral        |
| 32 yrs            | Hypertension | RF, ACPA, ANA | Active polyarthritis   | Oral methotrexate-bone marrow toxicity, azathioprine-ineffective, cyclosporine-ineffective combination of chloroquine, sulfasalazine, oral methotrexate-GI side effect subcutaneous methotrexate | Ineffective     | >75 continuously           | Adalimumab-ineffective, etanercept-ineffective, golimumab-ineffective | Nonresponder                   | Peripheral and axial |
| 40 yrs            | Sjögren's syndrome, neurofibromatosis | RF, ACPA, ANA, aCL IgM | Severe glandular symptoms, active polyarthritis | Leflunomide-ineffective, oral methotrexate-hepatotoxicity | Nonresponder     | —                        | Etanercept         | Just started                   | Peripheral        |

RA: rheumatoid arthritis, ANA: anti-nuclear antibody, ACPA: anti-citrullinated peptide antibody, aCL IgM: anti-cardiolipin antibody immunoglobulin M, DMARD: disease-modifying antirheumatic drugs, and PED: prednisolone equivalent dose.
DMARDs. All patients of the RA + psoriasis group were treated with biologicals and 2 patients (40%) needed to switch to another biological therapy, while in the RA group only 1 patient (20%) received biological therapy and all (100%) patients were in remission (defined as Das28 <2.1) (Tables 1 and 2). In the SLE + psoriasis group 7 patients had comorbidities (87.5%) as compared to the 6 patients (75%) in the SLE-only group. Similar to the RA groups there were no significant differences in immunological markers between the 2 groups. Otherwise, in the SLE + psoriasis group 5 patients (62.5%) had relapse, 2 patients (25%) had worsening outcome, and only 1 patient (12.5%) was in remission when compared to the SLE group, where all patients were in remission. In the SLE + psoriasis group all patients received more than 1 immunosuppressive agent and the systemic lupus international collaborating clinics (SLICC) index was elevated in 7 patients (87.5%) compared to the SLE group (37.5%). The average dose of corticosteroids (PED) was 17.5 mg in the SLE + psoriasis group and 11.4 mg in the SLE-only group (Tables 3 and 4).

4. Discussion

The overlap between psoriasis and autoimmune diseases is unusual. Differential diagnostic problems may also occur. The prevalence of psoriasis in African Americans is 1.3% compared to the 2.5% in Caucasians [17]. In our database we found 25 patients (0.545%) with psoriasis from the 4344 autoimmune disorders. In the general population the prevalence of skin psoriasis is around 2-3%. The lower prevalence, found in our data base, can probably be attributed to concurrent existence of national tertiary dermatology centre taking care of psoriatic patients. Therefore, our centre followed those patients who suffer from psoriatic arthritis or other autoimmune disorders. We have confirmed that the overlapping psoriasis and autoimmune diseases result in the worsening of the autoimmune diseases, reflected by the increased corticosteroid usage, worse response to the therapy, and the appearance of other comorbidities. We have not observed a significantly higher tendency to develop more autoimmune diseases in patients with psoriatic arthritis. Particularly, in case of patients with RA and psoriasis, physicians should be aware of the possible development of psoriatic arthritis. Despite the unusual association there are several similarities in the innate and adaptive pathways and genetic and environmental—including the infections—background between psoriasis and autoimmune diseases.

Th1, Th17, and IL-22-producing CD4 T cells in psoriasis and autoimmunity have recently been supposed. The concept of molecular mimicry is based on a structural similarity between a pathogen and a metabolite and self-structures. Epidemiological findings show a strong correlation between EBV infection and the risk of developing sclerosis multiplex, SLE, RA, and primer SS [18]. There are some gene variants evaluated to be involved and are common in the pathogenesis of the four diseases of cytokine pathways (e.g., IRF5, STAT4, and TNFSF4) leading to the development of autoimmunity [19]. Regarding the genetic association between psoriasis and autoimmunity, TNF-alpha-induced protein 3 (TNFAIP3) has been shown to be a major candidate. Multiple variants of TNFAIP3 could modulate development of autoimmunity in different diseases. The TNFAIP3 gene region has been implicated in the susceptibility to multiple autoimmune diseases in Europe. SNPs ~ 185 kb upstream from the TNFAIP3 gene have a strong association with risk of RA, type 1 diabetes (T1D), celiac disease (CeD), and Crohn’s disease [20]. Two independent studies regard the association between TNFAIP3 and SLE in a European cohort [21, 22]. Wu et al. have confirmed in a well-powered, genetic case-control study
Table 3: Patient characteristics with SLE associated with psoriasis.

| The age of SLE onset | Comorbidity | Immunoserology | Actual clinical status | Therapy | Arthritis psoriatica | Corticosteroids (mg PED) | SLICC |
|----------------------|-------------|----------------|------------------------|---------|----------------------|--------------------------|-------|
| 27 yrs               | Lupus nephritis, autoimmune thyroiditis | ANA, aSSA, aSSB, aTPO | Relapsing, remission by MMF | Cyclophosphamide, mycophenolate mofetil, methylprednisolone | Peripheral | 25 | 1 |
| 54 yrs               | Hypertension, gout, ischaemic heart disease, COPD, cataract | ANA, a-dsDNA | Relapsing | Chloroquine, azathioprine, methylprednisolone, etanercept | Axial | 12.5 | 4 |
| 45 yrs               | — | ANA, a-SSA | Remission | Oral methotrexate, leflunomide, chloroquine | — | — | 0 |
| 24 yrs               | Raynaud's syndrome, cutaneous vasculitis | ANA, a-dsDNA, a-SSA, aSSB, β2GPI IgG, hypocomplementaemia | Relapsing | Methylprednisolone, azathioprine, intravenous cyclophosphamide, IVIG, plasmapheresis | — | 30 | 1 |
| 33 yrs               | Autoimmune thyroiditis, nephrotic syndrome | ANA, a-TPO, lupus anticoagulant, aCL IgM | Relapsing | Methylprednisolone, chloroquine, oral methotrexate, | — | 10 | 1 |
| 57 yrs               | Sjögren's syndrome | ANA, a-SSA, a-SSB, a-dsDNA, hypocomplementaemia | Relapsing | Oral methotrexate, methylprednisolone, sulfasalazine, intravenous cyclophosphamide | — | 20 | 1 |
| 58 yrs               | Sjögren’s syndrome, urticaria vasculitis, ILD | ANA, a-dsDNA, a-chromatin, hypocomplementaemia | Worsening of ILD, psoriasis, immunoserology | Oral methotrexate, sulfasalazine, intravenous cyclophosphamide | Axial | 30 | 1 |
| 29 yrs               | Sjögren’s syndrome | ANA, a-dsDNA, a-SSA, anti-RNP, a-U1RNP, a-TG | Worsening of psychosis, thrombocytopenia | Methylprednisolone | — | 12.5 | 1 |

SLE: systemic lupus erythematosus, COPD: chronic obstructive pulmonary disease, ILD: interstitial lung disease, ANA: anti-nuclear antibody, ACPA: anti-citrullinated peptide antibody, a-SSA: anti-Sjögren's syndrome A antibody, a-SSB: anti-Sjögren's syndrome B antibody, anti-RNP: anti-ribonucleoprotein antibody, a-dsDNA: anti-double stranded deoxyribonucleic acid antibody, β2GPI IgG: beta 2 glycoprotein I IgG, aCL IgM: anti-cardiolipin antibody immunoglobulin M, aU1RNP: anti-U1 ribonucleoprotein antibody, a-TG: anti-thyroglobulin antibody, a-TPO: anti-thyroid peroxidase antibody, MMF: mycophenolate mofetil, PED: prednisolone equivalent dose, and SLICC: systemic lupus international collaborating clinics.

that both psoriasis and autoimmune diseases have complex genetic basis; multiple genes contribute to disease risk [23]. Overlapping of some gene locations of different autoimmune diseases has been known and supports common pathogenic gene variants (PTPN 22, Csk, PAG, PSTPIPI, PDCDI, SLC9A3R1, CARD15, and SUMO4) transcript within these diseases [24]. TNF-alpha polymorphism or TNF-alpha can increase the development of psoriasis or psoriatic arthritis. TNF inhibitors are effective in the treatment of psoriasis as well as in RA; however they can induce antinuclear antibodies and even lupus [25].

Interleukin-17 is a Th17 cytokine associated with inflammation, autoimmunity, and defence against some bacteria; it has been implicated in many chronic autoimmune diseases including psoriasis, Crohn's disease, autoimmune uveitis, SLE, ankylosing spondylitis, asthma, multiple sclerosis, and systemic sclerosis [26]. The pathophysiologic relevance of the IL-23-IL-17 axis in autoinflammatory diseases is highlighted by the clinical efficacy of antibodies targeting IL-23/IL-12 p40 and IL-17 in treating psoriasis, as well as the other systemic autoimmune diseases [27]. The level of IL-17 was significantly higher in serum of SLE patients than in normal controls, indicating that IL-17 may trigger the inflammatory process, although no correlation was found between serum IL-17 levels and disease manifestation or SLEDAI [28]. In general, the common IL-23-IL-17 axis may also initiate and maintain the coexistence of psoriasis and other systemic autoimmune diseases [27, 28].

The other prominent cytokine highlighting the common pathway is interferon- (IFN-) alpha, mainly produced by
### Table 4: Patient characteristics with SLE only.

| The age of SLE onset | Comorbidity | Immunoserology | Actual clinical status | Therapy | Corticosteroids (mg PED) | SLICC |
|----------------------|-------------|----------------|------------------------|---------|--------------------------|-------|
| 27 yrs               | —           | ANA, a-SSA, a-SSB, a-U1RNP, hypocomplementaemia | Remission | Azathioprine, low-dose corticosteroid | 13.75 | 0 |
| 54 yrs               | Gout, diabetes mellitus, COPD, ischemic heart disease | ANA, a-dsDNA, a-chromatin | Remission | Low-dose corticosteroid | 12.5 | 1 |
| 45 yrs               | —           | ANA, a-Sm, a-SSA, a-U1RNP, aCL IgM | Remission | — | 20 | 2 |
| 24 yrs               | Raynaud’s syndrome, Sjögren’s syndrome, Hashimoto-thyroiditis, seronegative rheumatoid arthritis (erosive polyarthritis), idiopathic thrombotic purpura | ANA, a-ENA, a-SSA, a-dsDNA, a-Sm, a-TPO | Remission | — | 10 | 0 |
| 33 yrs               | Sjögren’s syndrome | ANA, a-dsDNA, a-SSA, a-SSB, aCL IgM | Remission | — | 8.7 | 0 |
| 58 yrs               | Sjögren’s syndrome, type 2 diabetes mellitus | ANA, a-dsDNA, a-SSA, a-SSB, | Remission | — | 8.75 | 0 |
| 57 yrs               | Rheumatoid arthritis, sacroiliitis | ANA, a-ACPA, a-dsDNA, a-Sm, a-U1RNP | Remission | — | 7.5 | 0 |
| 29 yrs               | Rheumatoid arthritis, asthma bronchial, aseptic femur-head necrosis, cataract, glaucoma | ANA, a-ACPA, a-dsDNA | Remission | — | 10 | 2 |

SLE: systemic lupus erythematosus, COPD: chronic obstructive pulmonary disease, ILD: interstitial lung disease, ANA: anti-nuclear antibody, a-SSA: anti-Sjögren’s syndrome A antibody, a-SSB: anti-Sjögren’s syndrome B antibody, a-chromatin: anti-chromatin antibody, anti-RNP: anti-ribonucleoprotein antibody, a-dsDNA: anti-double stranded deoxyribonucleic acid antibody, anti-Sm: anti-Smith antibody, aCL IgM: anti-cardiolipin antibody immunoglobulin M, a-U1RNP: anti-U1 ribonucleoprotein antibody, a-TPO: anti-thyroid peroxidase antibody, MMF: mycophenolate mofetil, PED: prednisolone equivalent dose, and SLICC: systemic lupus international collaborating clinics.
plasmacytoid dendritic cells (PDCs) [29]. IFN-alpha plays a pivotal role in the development of SLE, insulin-dependent diabetes mellitus (IDDM), or RA. In psoriatic lesions plasmacytoid dendritic cell infiltrations have been shown, indicating that IFN-alpha may contribute to the pathogenesis of these diseases [29–32].

The humoral and cellular immunity have been shown to act against endothelial antigens and moreover it has a greater risk of atherosclerosis in both diseases as RA and SLE. So, these processes highlighted the significance of autoimmunity in atherosclerotic processes. Both angiogenic and oxidative pathways have a common role in the pathophysiology of psoriasis and atherosclerosis. Psoriasis and autoimmune diseases have a strong relationship with lipid metabolism and oxidative stress. Heat shock protein (Hsp) and human Hsp are known as possible pathogenic links between infection and atherosclerosis, as well as infection and autoimmunity [33, 34]. However, the immune-mediated inflammatory disease (IMID) is a group of diseases without exact etiology, but involving common inflammatory pathways resulting in many diseases as psoriasis, psoriatic arthritis and atherosclerosis, also. Psoriasis and autoimmune diseases also associate with an increased risk of atherosclerosis. Activated inflammatory cells and proinflammatory cytokines contribute to the psoriatic lesions and the rupture of atherosclerotic plaque. Macrophages also interact with T cells and other cells via activation of the CD40-CD40 ligand pathway, which contributes to the atheromatous plaque rupture [34]. Anti-CD40 therapy has been shown to be efficacious in some autoimmune diseases, such as SLE, vasculitis, and pSS [35]. Several studies have shown the endothelial cell dysfunction, the deficiency of nitric oxide (NO)₂, elevated endothelin 1 (ET-1), angiotensin II (Ang II), plasminogen activator inhibitor 1 (PAI-1), and cellular adhesion molecules. Furthermore, other common pathogenic factors such as the Toll-like receptors (TLR2 and TLR4) play key roles in atherosclerosis. TLR2 and TLR4 bind to components of gram positive and gram negative bacteria which could be a pathogenic factor in autoimmunity, as mentioned above [34].

Serum leptin, resistin, and lipocalin are increased in psoriasis patients and have a potential important role for developing insulin resistance and cardiovascular disease in psoriasis. An adipose tissue secreted cytokine, called adiponectin, is able to improve insulin resistance. Its serum level is decreased in psoriatic patients. The decreased level of different adipokines and Th17 cytokine has also associated in patients with psoriasis and autoimmune diseases, as well. However, leptin, adiponectin, resistin, and visfatin play a significant role in physiopathology of several inflammatory diseases. Moreover, all are involved strongly in other relevant inflammatory conditions and autoimmune disorders [36].

Nutritional compounds and drugs also trigger autoimmune disease. There are some data about the association of the early exposure to dietary cow’s milk proteins and a decreased risk of T1D; tienilic acid, dihydralazine, and halothane have been reported to induce autoimmune hepatitis. Stress and smoking are also associated susceptibilities to many autoimmune diseases [37].

Moreover, there is also strong association between autoimmunity and psoriasis when analyzing new bone formations and bone erosion as cellular biomarkers such as osteoclast precursors; osteoprotegerin (OPG), matrix metalloproteinase 3, serum IL-6, and IL-2R alpha were found elevated. OPG is produced not only in bone but also in several other tissues, including the cardiovascular system, lungs, kidneys, immune tissues, and blood vessels. In vascular system, increased OPG levels may be related to endothelial lesion, intimal hyperplasia, smooth cell hypertrophy, or advanced plaque calcification [38].

5. Summary

We believe that further prospective, cohort studies are required to determine real frequency of psoriasis in various autoimmune diseases as well as the incidence of autoimmune diseases within psoriatic patients. Positive and negative prognostic factors are still to be identified. The characteristics and outcome of autoimmune diseases and psoriasis also have to be followed.

Our present findings suggest that psoriasis exists as a negative predictive factor for the clinical outcome of autoimmune diseases. Despite there being several similarities between the pathogenesis of psoriasis and autoimmune diseases it was surprising to find the low frequencies of coexistence. Patients with RA and psoriasis are more likely to receive biological therapy, while patients with SLE and psoriasis need significant higher doses of glucocorticoids. TNF-α inhibitors are effective in the treatment of psoriasis; however they can induce antinuclear antibodies and even lupus. Therapeutic considerations have to be done in overlapping cases. Biologicals with different ways of action, for example, targeting of IL-17 and IL-23, dendritic cell suppression, might reduce activity of both diseases. Röhn et al. and de Carvalho et al. explored the fact that neutralization of IL-17 by passive and active vaccination may be a novel therapeutic approach for the treatment of SLE and atherosclerosis [39, 40]. Targeting IFN-alpha, RANK-RANKL, and CD40-CD40L system could also be beneficial for the prevention and early therapeutic intervention in psoriasis and other related autoimmune diseases [30, 34, 35, 38].

Conflict of Interests

The authors declare that there is no conflict of interests regarding the publication of this paper.

Acknowledgment

All of the charges will be paid by Swedish Orphan Biovitrum.

References

[1] S. K. Raychaudhuri, E. Maverakis, and S. P. Raychaudhuri, “Diagnosis and classification of psoriasis,” Autoimmunity Reviews, vol. 13, no. 4–5, pp. 490–495, 2014.
[2] J. J. Wu, T. U. Nguyen, K. Y. T. Poon, and L. J. Herrinton, “The association of psoriasis with autoimmune diseases,” *Journal of the American Academy of Dermatology*, vol. 67, no. 5, pp. 924–930, 2012.

[3] D. A. Jones, N. Yawalkar, K.-Y. Suh, S. Sadat, B. Rich, and T. S. Kupper, “Identification of autoantigens in psoriatic plaques using expression cloning,” *Journal of Investigative Dermatology*, vol. 123, no. 1, pp. 93–100, 2004.

[4] E. Y. M. G. Fung, D. J. Smyth, J. M. M. Howson et al., “Analysis of 17 autoimmune disease-associated variants in type I diabetes identifies 6q23/TNFAP1P3 as a susceptibility locus,” *Genes & Immunity*, vol. 10, no. 2, pp. 188–191, 2009.

[5] D. Aletaha, T. Neogi, A. J. Silman et al., “2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative,” *Annals of the Rheumatic Diseases*, vol. 62, no. 9, pp. 1580–1588, 2010.

[6] S. C. Shiboski, C. H. Shiboski, L. A. Criswell et al., “American College of rheumatology classification criteria for Sjogren’s syndrome: a data-driven, expert consensus approach in the Sjogren’s International Collaborative Clinical Alliance cohort,” *Arthritis Care and Research*, vol. 64, no. 4, pp. 475–487, 2012.

[7] M. Petri, A. M. Orbai, G. S. Alarcón et al., “Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus,” *Arthritis & Rheumatology*, vol. 64, no. 8, pp. 2677–2686, 2012.

[8] F. M. Wiggery, “Raynaud’s phenomenon,” *Current Opinion in Rheumatology*, vol. 5, no. 6, pp. 773–784, 1993.

[9] N. Basu, R. Watts, I. Bajema et al., “EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis,” *Annals of the Rheumatic Diseases*, vol. 69, no. 10, pp. 1744–1750, 2010.

[10] F. van den Hoogen, D. Khanna, J. Fransen et al., “2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative,” *Annals of the Rheumatic Diseases*, vol. 72, no. 11, pp. 1747–1755, 2013.

[11] M. Mosca, C. Tani, S. Vagnani et al., “The diagnosis and classification of undifferentiated connective tissue diseases,” *Journal of Autoimmunity*, vol. 48–49, pp. 50–52, 2014.

[12] J. A. Gómez-Puerta and R. Cervera, “Diagnosis and classification of the antiphospholipid syndrome,” *Journal of Autoimmunity*, vol. 48–49, pp. 20–25, 2014.

[13] J. C. Milisenda and A. Selva-O’Callaghan, “The diagnosis and classification of polymyositis,” *Journal of Autoimmunity*, vol. 48–49, pp. 118–122, 2014.

[14] C. Tani, L. Carli, S. Vagnani et al., “The diagnosis and classification of mixed connective tissue disease,” *Journal of Autoimmunity*, vol. 48–49, pp. 46–49, 2014.

[15] D. D. Gladman, C. Antoni, P. Mease, D. O. Clegg, and O. Nash, “Psoriatic arthritis: epidemiology, clinical features, course, and outcome,” *Annals of the Rheumatic Diseases*, vol. 64, no. 2, pp. ii4–ii7, 2005.

[16] L. Congi and E. Roussou, “Clinical application of the CASPAR criteria for psoriatic arthritis compared to other existing criteria,” *Clinical and Experimental Rheumatology*, vol. 28, no. 3, pp. 304–310, 2010.

[17] J. M. Gelfand, R. S. Stern, T. Nijsten et al., “The prevalence of psoriasis in African Americans: results from a population-based study,” *Journal of the American Academy of Dermatology*, vol. 52, no. 1, pp. 23–26, 2005.

[18] A. H. Draborg, K. Duus, and G. Houen, “Epstein-barr virus in systemic autoimmune diseases,” *Clinical and Developmental Immunology*, vol. 2013, Article ID 535738, 9 pages, 2013.

[19] J. P. Lodolce, L. E. Kolodziej, L. Rhee et al., “African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity,” *The Journal of Immunology*, vol. 184, no. 12, pp. 7001–7009, 2010.

[20] J. P. Lodolce, L. E. Kolodziej, L. Rhee et al., “African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity,” *Journal of Immunology*, vol. 184, no. 12, pp. 7001–7009, 2010.

[21] P. S. Ramos, L. A. Criswell, K. L. Moser et al., “A comprehensive analysis of shared loci between systemic lupus erythematosus (SLE) and sixteen autoimmune diseases reveals limited genetic overlap,” *PLoS Genetics*, vol. 7, no. 12, Article ID e1002406, 2011.

[22] I. Adrianto, F. Wen, A. Templeton et al., “Association of a functional variant downstream of TNFAIP3 with systemic lupus erythematosus,” *Nature Genetics*, vol. 43, no. 3, pp. 253–258, 2011.

[23] J. J. Wu, T. U. Nguyen, K.-Y. T. Poon, and L. J. Herrinton, “The association of psoriasis with autoimmune diseases,” *Journal of the American Academy of Dermatology*, vol. 67, no. 5, pp. 924–930, 2012.

[24] A. M. Bowcock, “The genetics of psoriasis and autoimmunity,” *Annual Review of Genomics and Human Genetics*, vol. 6, pp. 93–122, 2005.

[25] V. L. Williams and P. R. Cohen, “TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists,” *International Journal of Rheumatology*, vol. 50, no. 5, pp. 619–625, 2011.

[26] S. K. Bedoya, B. Lam, K. Lau, and J. Larkin III, “Th17 cells in immunity and autoimmunity,” *Clinical and Developmental Immunology*, vol. 2013, Article ID 986789, 16 pages, 2013.

[27] M. A. Lowes, C. B. Russell, D. A. Martin, J. E. Towne, and J. G. Krueger, “The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses,” *Trends in Immunology*, vol. 34, no. 4, pp. 174–181, 2013.

[28] F. B. Vincent, M. Northcott, A. Hoi, F. Mackay, and E. F. Morand, “Clinical associations of serum interleukin-17 in systemic lupus erythematosus,” *Arthritis Research and Therapy*, vol. 15, no. 4, article R97, 2013.

[29] W. Cao, “Pivotal functions of plasmacytoid dendritic cells in systemic autoimmune pathogenesis,” *Journal of Clinical & Cellular Immunology*, vol. 5, no. 2, pp. 212, 2014.

[30] S. H. Kasim, J. Jordan, J. Schreiter, S. Adhikarakunnathu, F. Baribaud, and L. San Mateo, “Systematic identification of novel SLE related autoantibodies responsible for type I IFN production in human plasmacytoid dendritic cells,” *Cellular Immunology*, vol. 284, no. 1-2, pp. 119–128, 2013.

[31] H. L. Wright, H. B. Thomas, R. J. Moots, and S. W. Edwards, “Interferon gene expression signature in rheumatoid arthritis neutrophils correlates with a good response to TNFi therapy,” *Rheumatology*, 2014.

[32] E. P. Prens, M. Kant, G. van Dijk, L. I. van der Wel, S. Mourits, and L. van der Fits, “IFN-α enhances poly-IC responses in human keratinocytes by inducing expression of cytosolic innate RNA receptors: relevance for psoriasis,” *Journal of Investigative Dermatology*, vol. 128, no. 4, pp. 932–938, 2008.

[33] X. Lu and V. Kakkar, “The role of Heat Shock Protein (HSP) in atherosclerosis: pathophysiology and clinical opportunities,” *Current Medicinal Chemistry*, vol. 17, no. 10, pp. 957–973, 2010.
[34] D. Siegel, S. Devaraj, A. Mitra, S. P. Raychaudhuri, S. K. Raychaudhuri, and I. Jialal, “Inflammation, atherosclerosis, and psoriasis,” *Clinical Reviews in Allergy & Immunology*, vol. 44, no. 2, pp. 194–204, 2013.

[35] J. H. Xie, A. P. Yamniuk, V. Borowski et al., “Engineering of a novel anti-CD40L domain antibody for treatment of autoimmune diseases,” *Journal of Immunology*, vol. 192, no. 9, pp. 4083–4092, 2014.

[36] J. Conde, M. Scotece, R. Gómez et al., “Adipokines: Biofactors from white adipose tissue. A complex hub among inflammation, metabolism, and immunity,” *Biofactors*, vol. 37, no. 6, pp. 413–420, 2011.

[37] K. H. Costenbader and E. W. Karlson, “Cigarette smoking and autoimmune disease: what can we learn from epidemiology?” *Lupus*, vol. 15, no. 11, pp. 737–745, 2006.

[38] M. F. McCarty and J. J. DiNicolantonio, “The molecular biology and pathophysiology of vascular calcification,” *Postgraduate Medicine*, vol. 126, no. 2, pp. 54–64, 2014.

[39] T. A. Röhn, G. T. Jennings, M. Hernandez et al., “Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis,” *European Journal of Immunology*, vol. 36, no. 11, pp. 2857–2867, 2006.

[40] J. F. de Carvalho, R. M. R. Pereira, and Y. Shoenfeld, “Vaccination for atherosclerosis,” *Clinical Reviews in Allergy & Immunology*, vol. 38, no. 2-3, pp. 133–140, 2010.